Trombonet coated tablets 0.075 №30


Manufacturer: Ukraine



Prevention of manifestations of atherothrombosis in adults: in patients after myocardial infarction (the beginning of treatment – a few days, but no later than 35 days after the onset), ischemic stroke (the beginning of treatment – 7 days, but no later than 6 months after the onset ), or who have been diagnosed with peripheral arterial disease (arterial damage and atherothrombosis of the vessels of the lower extremities); in patients with acute coronary syndrome: with acute coronary syndrome without ST segment elevation (unstable angina or myocardial infarction without Q wave), including in patients who had a stent installed during percutaneous coronary angioplasty, in combination with acetylsalicylic acid; with acute myocardial infarction with an ST segment elevation in combination with acetylsalicylic acid (in patients receiving standard medication and who are shown thrombolytic therapy). Prevention of atherothrombotic and thromboembolic events in atrial fibrillation. Clopidogrel in combination with ASA is indicated for adult patients with atrial fibrillation, who have at least one risk factor for the occurrence of vascular events, who have contraindications for treatment with vitamin K antagonists (aVK) and who have a low risk of bleeding, for the prevention of atherothrombotic and thromboembolic events including stroke.